New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

Abstract

HER2 positivity is predictive of the response to anti-HER2 therapies. The treatment of HER2-positive tumors is continuously improving through the development of new anti-HER2-directed agents. Many different anti-HER2 therapies are now available which belong to the classes of anti-HER2 antibodies, tyrosine kinase inhibitors (TKI) and antibody-drug conjugates (ADC). A combination of trastuzumab, pertuzumab and a taxane (THP) remains the preferred first-line (1L) therapy, whereas T‑DXd is the new standard for 2L metastatic breast cancer based on a highly significant improvement in progression-free survival compared to T-DM1 as shown in the DESTINY-Breast03 study. A tucatinib-based regimen (dual anti-HER2 therapy with trastuzumab and tucatinib plus capecitabine) is the preferred 3L option, which may already be used for 2L treatment in patients with active brain metastases. Different anti-HER2 therapies are available in the 3L setting and beyond. Molecular biomarkers in addition to the quantification of HER2 expression, such as the PD‑L1 status and PIK3CA mutations, can further guide the decision-making process in the future.

Keywords

HER2-positive breast cancer

Publication History

Article published online:
12 September 2023

• Literatur

• 1 Slamon DJ, Clark GM, Wong SG. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 1987; 235: 177-182
• 2 Slamon DJ, Leyland-Jones B, Shak S. et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine 2001; 344: 783-792
• 3 Taran FA, Fasching PA, Volz B. et al. Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry. Cancer Research 2018; 78: P5-21
• 4 Deluche E, Antoine A, Bachelot T. et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. European journal of cancer (Oxford, England : 1990) 2020; 129: 60-70
• 5 Wolff AC, Somerfield MR, Dowsett M. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology–College of American Pathologists Guideline Update. Archives of Pathology & Laboratory Medicine 2023;
• 6 Loibl S, Gianni L. HER2-positive breast cancer. Lancet (London, England) 2017; 389: 2415-2429
• 7 Tarantino P, Hamilton E, Tolaney SM. et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; 38: 1951-1962
• 8 Banerji U, van Herpen CML, Saura C. et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. The Lancet Oncology 2019; 20: 1124-1135
• 9 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine 2022; 387: 9-20
• 10 Chan A, Moy B, Mansi J. et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical breast cancer 2021; 21: 80-91.e87
• 11 Martin M, Holmes FA, Ejlertsen B. et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2017; 18: 1688-1700
• 12 Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. The New England journal of medicine 2007; 357: 39-51
• 13 Vogel CL, Cobleigh MA, Tripathy D. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20: 719-726
• 14 Fehrenbacher L, Cecchini RS, Geyer CE. et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; 38: 444-453
• 15 Ismael G, Hegg R, Muehlbauer S. et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet Oncology 2012; 13: 869-878
• 16 Jackisch C, Stroyakovskiy D, Pivot X. et al. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. JAMA Oncology 2019; 5: e190339-e190339
• 17 Thill M. Biosimilar Trastuzumab in Clinical Trials: Differences or Not?. Breast care (Basel, Switzerland) 2019; 14: 17-22
• 18 Baselga J, Cortés J, Kim SB. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England journal of medicine 2012; 366: 109-119
• 19 Franklin MC, Carey KD, Vajdos FF. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer cell 2004; 5: 317-328
• 20 Tan AR, Im SA, Mattar A. et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet Oncology 2021; 22: 85-97
• 21 Nordstrom JL, Gorlatov S, Zhang W. et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Research 2011; 13: R123
• 22 Lewis Phillips GD, Li G, Dugger DL. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290
• 23 Doi T, Shitara K, Naito Y. et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. The Lancet Oncology 2017; 18: 1512-1522
• 24 Ogitani Y, Hagihara K, Oitate M. et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer science 2016; 107: 1039-1046
• 25 Nadal-Serrano M, Morancho B, Escrivá-de-Romaní S. et al. The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers 2020; 12
• 26 Graziani EI, Sung M, Ma D. et al. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. Molecular cancer therapeutics 2020; 19: 2068-2078
• 27 Konecny GE, Pegram MD, Venkatesan N. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639
• 28 Rabindran SK, Discafani CM, Rosfjord EC. et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64: 3958-3965
• 29 Moulder SL, Borges VF, Baetz T. et al. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clinical Cancer Research 2017; 23: 3529-3536
• 30 Ma F, Li Q, Chen S. et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology 2017; 35: 3105-3112
• 31 Swain SM, Baselga J, Kim S-B. et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine 2015; 372: 724-734
• 32 Verma S, Miles D, Gianni L. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine 2012; 367: 1783-1791
• 33 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. The New England journal of medicine 2020; 382: 610-621
• 34 Krop IE, Kim SB, González-Martín A. et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet Oncology 2014; 15: 689-699
• 35 Rugo HS, Bianchini G, Cortes J. et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO open 2022; 7: 100553
• 36 Rugo HS, Crossno CL, Gesthalter YB. et al. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO oncology practice 2023; 19 (08) 539-546
• 37 Geyer CE, Forster J, Lindquist D. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine 2006; 355: 2733-2743
• 38 Cameron D, Casey M, Oliva C. et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. The oncologist 2010; 15: 924-934
• 39 Saura C, Oliveira M, Feng Y-H. et al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology 2020; 38: 3138-3149
• 40 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England journal of medicine 2020; 382: 597-609
• 41 Tolaney SM, Barry WT, Dang CT. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England journal of medicine 2015; 372: 134-141
• 42 Tolaney SM, Guo H, Pernas S. et al. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; 37: 1868-1875
• 43 von Minckwitz G, Procter M, de Azambuja E. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. The New England journal of medicine 2017; 377: 122-131
• 44 Loibl S, Jassem J, Sonnenblick A. et al. VP6–2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8. 4 years’ follow-up. ESMO Virtual Plenary 2022; 33 (09) 986-987
• 45 Gianni L, Pienkowski T, Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology 2012; 13: 25-32
• 46 von Minckwitz G, Huang CS, Mano MS. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England journal of medicine 2019; 380: 617-628
• 47 Geyer Jr CE, Untch M, Prat A. et al. Abstract OT1–02–03: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). Cancer Research 2022; 82
• 48 Swain SM, Miles D, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology 2020; 21: 519-530
• 49 Cortés J, Kim SB, Chung WP. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. The New England journal of medicine 2022; 386: 1143-1154
• 50 Hurvitz SA, Hegg R, Chung WP. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet (London, England) 2022;
• 51 Modi S, Saura C, Yamashita T. et al. Abstract PD3–06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer. Cancer Research 2021; 81: PD3-06
• 52 Manich C, Modi S, Krop I. et al. 279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01). Annals of Oncology 2021; 32: S485-S486
• 53 Krop I, Park Y, Kim S-B. et al. Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02. Cancer Research 2023; 83: GS2-01
• 54 Martínez-Sáez O, Prat A. Current and Future Management of HER2-Positive Metastatic Breast Cancer. JCO oncology practice 2021; 17: 594-604
• 55 Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO open 2022; 7: 100343
• 56 Curigliano G, Mueller V, Borges V. et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Annals of oncology : official journal of the European Society for Medical Oncology 2022; 33: 321-329
• 57 Diéras V, Miles D, Verma S. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology 2017; 18: 732-742
• 58 Krop IE, Kim SB, Martin AG. et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. The Lancet Oncology 2017; 18: 743-754
• 59 Cameron D, Casey M, Press M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast cancer research and treatment 2008; 112: 533-543
• 60 Blackwell KL, Burstein HJ, Storniolo AM. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28: 1124-1130
• 61 Kaufman B, Mackey JR, Clemens MR. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27: 5529-5537
• 62 Huober J, Fasching PA, Barsoum M. et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – results of the eLEcTRA trial. Breast (Edinburgh, Scotland) 2012; 21: 27-33
• 63 Johnston S, Pippen J, Pivot X. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27: 5538-5546
• 64 Rimawi M, Ferrero JM, de la Haba-Rodriguez J. et al. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; 36: 2826-2835
• 65 Johnston SRD, Hegg R, Im SA. et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; 39: 79-89
• 66 Tolaney SM, Wardley AM, Zambelli S. et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. The Lancet Oncology 2020; 21: 763-775
• 67 Janni W, Fehm T, Müller V. et al. Abstract PD18–07: Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial. Cancer Research 2023; 83: PD18-07
• 68 Rugo HS, Im S-A, Cardoso F. et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology 2021; 7: 573-584
• 69 Xu B, Yan M, Ma F. et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Oncology 2021; 22: 351-360
• 70 Yan M, Ouyang Q, Sun T. et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. The Lancet Oncology 2022; 23: 353-361
• 71 Saura Manich C, O'Shaughnessy J, Aftimos PG. et al. LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Annals of Oncology 2021; 32: S1288
• 72 Meric-Bernstam F, Calvo E, Moreno V. et al. A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors. Journal of Clinical Oncology 2020; 38: 1039-1039
• 73 Kommission Mamma der Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO). Guidelines Breast Version 2023.1D. Therapy algorithms. Last update: 15.04.2023. https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
• 74 Gennari A, André F, Barrios CH. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2021; 32: 1475-1495
• 75 Ciruelos E, Villagrasa P, Pascual T. et al. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2020; 26: 5820-5829
• 76 Ciruelos EM, Garcia AA, Cortes J. et al. 130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype. Annals of Oncology 2021; 32: S77
• 77 Loibl S, Metzger O, Mandrekar S. et al. 369TiP PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Annals of Oncology 2018; 29
• 78 Loi S, Giobbie-Hurder A, Gombos A. et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. The Lancet Oncology 2019; 20: 371-382
• 79 Emens LA, Esteva FJ, Beresford M. et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. The Lancet Oncology 2020; 21: 1283-1295
• 80 Andre F, Hamilton EP, Loi S. et al. Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07). Journal of Clinical Oncology 2021; 39: TPS1096-TPS1096
• 81 Baselga J, Cortés J, Im SA. et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014; 32: 3753-3761
• 82 Baselga J, Lewis Phillips GD, Verma S. et al. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2016; 22: 3755-3763
• 83 Loibl S, Majewski I, Guarneri V. et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Annals of oncology : official journal of the European Society for Medical Oncology 2016; 27: 1519-1525
• 84 Krop IE, Paulson J, Campbell C. et al. Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. Journal of Clinical Oncology 2019; 37: 1012-1012
• 85 Denkert C, Lambertini C, Fasching PA. et al. Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. Journal of Clinical Oncology 2020; 38: 502-502
• 86 Kim SB, Wildiers H, Krop IE. et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. International journal of cancer 2016; 139: 2336-2342
• 87 Jain S, Shah AN, Santa-Maria CA. et al. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast cancer research and treatment 2018; 171: 371-381
• 88 Oliveira M, Ciruelos E, Morales S. et al. Solti-1507 IPATHER – A phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with pertuzumab and trastuzumab (HP) in patients with HER2-positive (HER2+) advanced breast cancer (ABC) and a PIK3CA mutation (mut): Results from the first safety cohort. Cancer Research 2022; 82: P1-18
• 89 Piccart M, Borrego M, Arkenau HT. et al. 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). Annals of Oncology 2021; 32: S478-S479
• 90 Hurvitz SA, Chia SKL, Ciruelos EM. et al. 352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC). Annals of Oncology 2020; 31: S389-S390
• 91 Fachinformation für Enhertu 100 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung. Stand Juli 2023.